AI Article Synopsis
- Amaranth is a resilient crop known for its nutritional benefits and the study aims to explore the antitumor properties of its protein isolate (MPI).
- MPI was tested on four cancer cell lines, showing varying levels of antiproliferative effects, with UMR106 being the most sensitive.
- The study suggests that MPI inhibits cell adhesion, induces cell death, and its effects depend on concentration, indicating its potential as an antitumor agent.
Article Abstract
Background: Amaranth is a crop that can be grown in different soils and climates, being resistant to high temperatures, drought, and some pests. The amaranth plant has nutritional qualities and desirable biological properties.
Aim Of The Study: The aim of the study is to investigate the potential antitumor properties of Amaranthus-mantegazzianus-protein isolate (MPI) and to elucidate the possible mechanism of action.
Methods: We use four different tumor-derived and in vitro-transformed cell lines with different morphology and tumorigenicity (MC3T3E1, UMR106, Caco-2, and TC7).
Results: The MPI showed an antiproliferative effect on four cell lines with different potencies. The tumor-cell line UMR106 was the most sensitive (IC(50): 1 mg/ml). This antiproliferative effect of the MPI was enhanced by protease treatment (IC(50): 0.5 after 30% hydrolysis). In addition, the MPI produced morphological changes and caused a rearrangement of the cytoskeleton in UMR106 cell line. In an attempt to elucidate the mechanism of action, we observed that the MPI inhibited cell adhesion and induced apoptosis and necrosis in the UMR106 cell line. In reversibility studies, we were able to observe both temporary and permanent cytostatic and cytotoxic effects on the part of the MPI, depending on its concentration.
Conclusions: we report a protein isolate from the seeds of Amaranthus mantegazzianus that exhibit potential antitumor properties and propose a putative mechanism of action.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00394-009-0051-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An antibody cocktail targeting two different CD73 epitopes enhances enzyme inhibition and tumor control.
Nat Commun
December 2024
Key Laboratory of Immune Response and Immunotherapy, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Scienes, Guangzhou, China.
CD73, an ectoenzyme responsible for adenosine production, is often elevated in immuno-suppressive tumor environments. Inhibition of CD73 activity holds great promise as a therapeutic strategy for CD73-expressing cancers. In this study, we have developed a therapeutic anti-human CD73 antibody cocktail, HB0045.
View Article and Find Full Text PDFAnti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3 T population.
Nat Commun
December 2024
Division of Plastic Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Secondary lymphedema is a common sequel of oncologic surgery and presents a global health burden still lacking pharmacological treatment. The infiltration of the lymphedematous extremities with CD4T cells influences lymphedema onset and emerges as a promising therapy target. Here, we show that the modulation of CD4FOXP3CD25regulatory T (T) cells upon anti-CTLA4 treatment protects against lymphedema development in patients with melanoma and in a mouse lymphedema model.
View Article and Find Full Text PDFMetaplastic breast cancer (MpBC) is a highly chemoresistant subtype of breast cancer with no standardized therapy options. A clinical study in anthracycline-refractory MpBC patients suggested that nitric oxide synthase (NOS) inhibitor NG-monomethyl-l-arginine (L-NMMA) may augment anti-tumor efficacy of taxane. We report that NOS blockade potentiated response of human MpBC cell lines and tumors to phosphoinositide 3-kinase (PI3K) inhibitor alpelisib and taxane.
View Article and Find Full Text PDFFerritin-Based Supramolecular Assembly Drug Delivery System for Aminated Fullerene Derivatives to Enhance Tumor-Targeted Therapy.
Adv Sci (Weinh)
December 2024
CAS Engineering Laboratory for Nanozyme, Key Laboratory of Protein and Peptide Pharmaceutical Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, P. R. China.
Owing to their attractive antitumor effects, aminated fullerene derivatives are emerging as promising therapeutic drugs for cancer. However, their in vivo applications are severely limited due to cation toxicity. To address this problem, human heavy chain ferritin (HFn), possessing natural biocompatibility is utilized, to develop a novel supramolecular assembly drug delivery system.
View Article and Find Full Text PDFEnhancing the efficacy of Zinc Oxide Nanoparticles by Beta-carotene conjugation for improved anti-microbial and anti-tumor therapy for Dental Application.
Pharm Dev Technol
December 2024
Department of Cariology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.
The increasing prevalence of dental pathogens and oral cancer calls for new therapeutic agents. Nanoparticle (NPs) based tumor therapy enables precise targeting and controlled drug release, improving anti-cancer treatment efficacy while reducing systemic toxicity. Zinc oxide NPs (ZnO NPs) are notable in nanomedicine for their exceptional physicochemical and biological properties.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!